https://www.proz.com/kudoz/english-to-russian/medical-pharmaceuticals/6535622-emea-h-c-00528-ii-0084.html
This site uses cookies. Some of these cookies are essential to the operation of the site, while others help to improve your experience by providing insights into how the site is being used. For more information, please see the ProZ.com privacy policy.
Cookie settings
  1. KudoZ™ Top
  2. English to Russian
  3. Medical: Pharmaceuticals

EMEA/H/C/00528/II/0084

Russian translation: ПОБЛС № EMEA/H/C/00528/II/0084

06:02 Jul 6, 2018
English to Russian translations [PRO]
Medical - Medical: Pharmaceuticals / клинические испытания
English term or phrase: EMEA/H/C/00528/II/0084
During the reporting period, the insulin detemir RMP was first updated from Version 17 to 18 in connection with EMEA/H/C/00528/II/0084 (post-approval commitment for Levemir® in the EU and Australia: a separate report based on descriptive statistics on the incidence of neoplasms with the combination of liraglutide and insulin [including insulin detemir]).
Tymur Buliekov
Ukraine
Local time: 04:49
Russian translation:ПОБЛС № EMEA/H/C/00528/II/0084
Explanation:
Это номер обозначает номер PSUR (по-русски ПОБЛC - периодически обновляемый отчет по безопасности лекарственного средства) для препарата детемир/левемир (названия в зависимости от страны). Часть номера EMEA/H/C/00528 - это номер препарата, а все вместе - номер пост-маркетингового отчета ПОБЛС.

Вот сведения об этом отчете:
15.3.23. Insulin detemir - LEVEMIR (CAP) - EMEA/H/C/000528/II/0084
Applicant: Novo Nordisk A/S
PRAC Rapporteur: Doris Stenver
Scope: Submission of the summary analysis report on the incidence of neoplasms with the combination of liraglutide and insulin detemir from the cardiovascular outcome trial for Victoza (liraglutide): study EX2211-3748 (LEADER: liraglutide effect and action in diabetes): a long-term, multicentre, international, randomized double-blind, placebo-controlled trial to
determine liraglutide effects on cardiovascular events. The RMP (version 18) is updated accordingly to delete the important potential risk of malignant neoplasms following combination treatment with insulin detemir, liraglutide and metformin
(стр. 72-73)
https://tinyurl.com/y8x6rs77


--------------------------------------------------
Note added at 21 days (2018-07-27 16:57:59 GMT) Post-grading
--------------------------------------------------

Мелочь, конечно, но как-то даже расхотелось помогать вам в дальнейшем...
Selected response from:

Natalie
Poland
Local time: 03:49
Grading comment
1 KudoZ points were awarded for this answer



Summary of answers provided
5 +1ПОБЛС № EMEA/H/C/00528/II/0084
Natalie
4 -1реестр...
Stanislav Korobov


  

Answers


10 mins   confidence: Answerer confidence 4/5Answerer confidence 4/5 peer agreement (net): -1
emea/h/c/00528/ii/0084
реестр...


Explanation:
И дальше - вот всё то, что вынесено в вопрос

--------------------------------------------------
Note added at 22 mins (2018-07-06 06:24:37 GMT)
--------------------------------------------------

Если ещё точнее, то можно, например, "запись" или "информация" (в реестре), так как цифры, стоящие в конце - это номер в этом реестре, относящийся к последним опубликованым данным о препаратеhttps://clinicaldata.ema.europa.eu/web/cdp/home

Stanislav Korobov
Ukraine
Local time: 04:49
Specializes in field
Native speaker of: Native in RussianRussian
PRO pts in category: 1220

Peer comments on this answer (and responses from the answerer)
disagree  Natalie: Это не реестр
2 hrs
Login to enter a peer comment (or grade)

2 hrs   confidence: Answerer confidence 5/5 peer agreement (net): +1
emea/h/c/00528/ii/0084
ПОБЛС № EMEA/H/C/00528/II/0084


Explanation:
Это номер обозначает номер PSUR (по-русски ПОБЛC - периодически обновляемый отчет по безопасности лекарственного средства) для препарата детемир/левемир (названия в зависимости от страны). Часть номера EMEA/H/C/00528 - это номер препарата, а все вместе - номер пост-маркетингового отчета ПОБЛС.

Вот сведения об этом отчете:
15.3.23. Insulin detemir - LEVEMIR (CAP) - EMEA/H/C/000528/II/0084
Applicant: Novo Nordisk A/S
PRAC Rapporteur: Doris Stenver
Scope: Submission of the summary analysis report on the incidence of neoplasms with the combination of liraglutide and insulin detemir from the cardiovascular outcome trial for Victoza (liraglutide): study EX2211-3748 (LEADER: liraglutide effect and action in diabetes): a long-term, multicentre, international, randomized double-blind, placebo-controlled trial to
determine liraglutide effects on cardiovascular events. The RMP (version 18) is updated accordingly to delete the important potential risk of malignant neoplasms following combination treatment with insulin detemir, liraglutide and metformin
(стр. 72-73)
https://tinyurl.com/y8x6rs77


--------------------------------------------------
Note added at 21 days (2018-07-27 16:57:59 GMT) Post-grading
--------------------------------------------------

Мелочь, конечно, но как-то даже расхотелось помогать вам в дальнейшем...

Natalie
Poland
Local time: 03:49
Specializes in field
Native speaker of: Russian
PRO pts in category: 13399

Peer comments on this answer (and responses from the answerer)
agree  Erzsébet Czopyk: excellent. Congrats Natalie
9 hrs
  -> Спасибо!
Login to enter a peer comment (or grade)



Login or register (free and only takes a few minutes) to participate in this question.

You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.

Return to KudoZ list

KudoZ™ translation help

The KudoZ network provides a framework for translators and others to assist each other with translations or explanations of terms and short phrases.

See also:
ProZ.com term search
Search millions of term translations